Key Highlights

  • Every name in this group rose in the Wednesday, October 28, 2026 snapshot. Davion Healthcare (NASDAQ:DAVI) headed the list at 39.00%, with NewGenIvf Group (NASDAQ:NIVF) second at 21.30%.
  • eHealth (NASDAQ:EHTH), a digital insurance marketplace, climbed 11.04%, Pulmonx (NASDAQ:LUNG), an emphysema device maker, added 7.07%, and Microbot Medical (NASDAQ:MBOT), a vascular robotics developer, gained 6.80%.
  • Pulmonx alone had a company release dated the prior session. For the other four, thin liquidity and positioning look consistent with the moves, though both remain inferences.
  • Scale varies enormously, from a Pulmonx revenue base in the tens of millions of dollars down to a pre-revenue Davion. Every quote is a thin pre-market snapshot that could shift before the open.

Davion Healthcare (NASDAQ:DAVI): a rebound in a new listing after a sharp fall

Davion Healthcare Plc (NASDAQ:DAVI) is an Irish developer of non-invasive home screening tests. The shares were quoted at USD 4.17 in the pre-market snapshot of Wednesday, October 28, 2026, up 39.00%. Working backwards, the prior close was near USD 3.00, which means the stock is recovering part of a 26% to 32% slide on Tuesday, October 27, 2026. Nothing dated on or just before the session accompanied the rise. The latest release, of Monday, October 26, 2026, described the Humaskan intellectual property purchase. A bounce on thin trading in a stock that began on Thursday, October 22, 2026 is the likelier story.

Payment for Humaskan comprises USD 2.5 million in cash, due by Friday, February 19, 2027, and 1,730,770 new ordinary shares at a fixed USD 13.00, worth about USD 22.5 million, to be issued Wednesday, January 20, 2027. Optimists point to a wider pipeline backed by a five-year GBP 30 million senior secured bond. Skeptics stress that revenue is nil, that the shares trade well below the deal value, and that the bond and new shares add obligations and dilution.

NewGenIvf Group (NASDAQ:NIVF): thin trading around a K25.ai stake

NewGenIvf Group Limited (NASDAQ:NIVF) runs fertility-related operations and holds technology investments. The stock traded at USD 1.40, up 21.30%, before the open, implying a prior close near USD 1.15. No dated company news appeared on or before Wednesday, October 28, 2026. Its last release, of Wednesday, September 30, 2026, reported closing a public offering at USD 0.07 a share. With a market value around USD 1.02 million, a move of this size looks driven by light trading. A share consolidation since then could explain the distance from the offering price, though that is conjecture.

The company holds 10% of K25.ai at a USD 100 million valuation. Under an agreement of Monday, July 27, 2026, it will buy a further 3% for USD 7.5 million at a USD 250 million valuation, putting the expected stake near USD 26 million. Net profit for the year ended Thursday, December 31, 2025 was USD 9.9 million. Critics point out that the stake is an unrealised mark, and that repeated capital raises, a Nasdaq market value test and a forbearance agreement of Tuesday, June 16, 2026 stay open.

eHealth (NASDAQ:EHTH): positioning ahead of the third quarter call

eHealth (NASDAQ:EHTH) is a health insurance marketplace that collects commissions on Medicare plans as well as individual and family plans. Its shares traded at USD 0.6104, up 11.04%, pre-market. Nothing dated Wednesday, October 28, 2026 or earlier came with the move. On Wednesday, October 21, 2026 the company scheduled its third quarter 2026 earnings call for Wednesday, November 4, 2026 at 5:00 p.m. ET, so the advance appears to be positioning ahead of that call alongside thin trading, an inference.

Second-quarter revenue of USD 33.6 million, reported Tuesday, August 4, 2026, was 45% lower than the USD 60.8 million of a year earlier, and the GAAP net loss was USD 23.6 million, or USD 1.18 per diluted share. Bulls rely on USD 101.0 million of liquidity and reiterated 2026 revenue guidance of USD 405.0 million to USD 445.0 million. Under USD 1.00, the share price matters for Nasdaq minimum bid rules as background only, since no notice has been disclosed.

Pulmonx (NASDAQ:LUNG): a return to growth in the third quarter

Pulmonx (NASDAQ:LUNG) makes the Zephyr valve used against severe emphysema. Its shares advanced 7.07% to USD 2.12 before the open. The third-quarter release of Tuesday, October 27, 2026 is the probable trigger, since it stated that revenue grew year on year again. Revenue was USD 22.8 million, up 6% on reported and constant currency bases, the latter removing exchange-rate effects. Zero China revenue continues, as the distributor has not restarted orders. Linking the report to the price move rests on timing, which is an inference.

Operating expenses dropped 18% to USD 24.9 million, and the net loss came to USD 8.4 million. Keeping full-year revenue guidance at USD 90 million to USD 92 million implies USD 23.8 million to USD 25.8 million in the fourth quarter. Critics focus on cash that fell to USD 52.7 million on Wednesday, September 30, 2026 from USD 69.8 million at year-end 2025, with a further USD 22 million drop expected in 2026.

Microbot Medical (NASDAQ:MBOT): commercial rollout with no dated catalyst

Microbot Medical (NASDAQ:MBOT) markets the LIBERTY endovascular robot, a single-use device for guiding instruments through blood vessels. The stock was at USD 1.10 pre-market, up 6.80%. Nothing dated Wednesday, October 28, 2026 or earlier came with the move. The newest release, of Tuesday, October 20, 2026, announced new patents. Interest in the commercial rollout and thin trading are the two inferred drivers.

The Form 10-Q for the quarter ended Tuesday, June 30, 2026 showed second-quarter revenue of USD 241,000 against cost of revenue of USD 884,000, and a net loss of USD 5.6 million. Cash and marketable securities totalled about USD 67.4 million. Supporters cite an exclusive three-year Israel distribution pact signed Tuesday, October 6, 2026, along with a CE Mark, a European conformity approval, expected late 2026 or early 2027. Critics point to a negative gross margin not expected to flip before 2027 and to dilution from its at-the-market programme.

Where Things Stand

Put plainly, the five share a healthcare label and a pre-market gain but no common driver. Pulmonx (NASDAQ:LUNG) moved on a dated results release, whereas Davion Healthcare (NASDAQ:DAVI), NewGenIvf Group (NASDAQ:NIVF), eHealth (NASDAQ:EHTH) and Microbot Medical (NASDAQ:MBOT) moved without one. How durable each move is depends on its balance sheet.

Coming up are the Federal Reserve decision due later on Wednesday, October 28, 2026, the eHealth call on Wednesday, November 4, 2026, the Davion share issue on Wednesday, January 20, 2027 and the Microbot CE Mark decision. Pre-market prices are snapshots that can change, and this is not investment advice.